http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2008126624-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-05 |
| filingDate | 2008-07-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2010-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2008126624-A |
| titleOfInvention | PHARMACEUTICAL NEUROPROTECTOR, ANTIOXIDANT, ANTIHYPOXANT, ANTIAPOPTOTIC AND MEMBRANOPROTECTIVE COMPOSITION AND METHOD OF TREATMENT |
| abstract | 1. Pharmaceutical neuroprotective, antioxidant, antihypoxant, antiapoptotic and membrane protective composition containing 100-250 mg of 3-hydroxypyridine or its pharmaceutically acceptable derivative, or a pharmaceutically acceptable salt of this derivative and 100-400 mg of choline alfoscerate, characterized in that it additionally contains 400- 500 mg of a pharmaceutically acceptable derivative of magnesium, 10-50 mg of pyridoxine or its pharmaceutically acceptable derivative, 10-50 mg of nicotinamide, 15-30 mg of idebenone, 15-30 mg of ubiquinone (coenzyme Q10) and 5-4 0 mg pharmaceutically acceptable derivative of zinc and pharmaceutically acceptable excipients. ! 2. The pharmaceutical composition according to claim 1, characterized in that the pharmaceutically acceptable derivative of 3-hydroxypyridine is 2-ethyl-6-methyl-3-hydroxypyridine or a pharmaceutically acceptable salt thereof. ! 3. The pharmaceutical composition of claim 2, wherein the pharmaceutically acceptable salt of the 3-hydroxypyridine derivative is 2-ethyl-6-methyl-3-hydroxypyridine hydrochloride or 2-ethyl-6-methyl-3-hydroxypyridine succinate. ! 4. The pharmaceutical composition according to claim 1, characterized in that the pharmaceutically acceptable derivative of magnesium is magnesium lactate or magnesium chloride. ! 5. The pharmaceutical composition according to claim 1, characterized in that the pharmaceutically acceptable derivative of pyridoxine is pyridoxalphosphate and pyridoxamine phosphate. ! 6. The pharmaceutical composition according to claim 1, characterized in that the pharmaceutically acceptable derivative of zinc is zinc citrate, or zinc sulfate, or zinc oxide. ! 7. Pharmaceutical composition |
| priorityDate | 2008-07-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 40.